vs
Prestige Consumer Healthcare Inc.（PBH）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是Rocket Lab Corp的1.6倍（$283.4M vs $179.7M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs -29.5%，领先45.9%），Rocket Lab Corp同比增速更快（35.7% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
PBH vs RKLB — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $179.7M |
| 净利润 | $46.7M | $-52.9M |
| 毛利率 | 55.5% | 38.0% |
| 营业利润率 | 29.1% | -28.4% |
| 净利率 | 16.5% | -29.5% |
| 营收同比 | -2.4% | 35.7% |
| 净利润同比 | -23.5% | -1.1% |
| 每股收益（稀释后） | $0.97 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $283.4M | $179.7M | ||
| Q3 25 | $274.1M | $155.1M | ||
| Q2 25 | $249.5M | $144.5M | ||
| Q1 25 | $296.5M | $122.6M | ||
| Q4 24 | $290.3M | $132.4M | ||
| Q3 24 | $283.8M | $104.8M | ||
| Q2 24 | $267.1M | $106.3M | ||
| Q1 24 | $277.0M | $92.8M |
| Q4 25 | $46.7M | $-52.9M | ||
| Q3 25 | $42.2M | $-18.3M | ||
| Q2 25 | $47.5M | $-66.4M | ||
| Q1 25 | $50.1M | $-60.6M | ||
| Q4 24 | $61.0M | $-52.3M | ||
| Q3 24 | $54.4M | $-51.9M | ||
| Q2 24 | $49.1M | $-41.6M | ||
| Q1 24 | $49.5M | $-44.3M |
| Q4 25 | 55.5% | 38.0% | ||
| Q3 25 | 55.3% | 37.0% | ||
| Q2 25 | 56.2% | 32.1% | ||
| Q1 25 | 57.3% | 28.8% | ||
| Q4 24 | 55.5% | 27.8% | ||
| Q3 24 | 55.5% | 26.7% | ||
| Q2 24 | 54.7% | 25.6% | ||
| Q1 24 | 54.8% | 26.1% |
| Q4 25 | 29.1% | -28.4% | ||
| Q3 25 | 29.1% | -38.0% | ||
| Q2 25 | 28.8% | -41.3% | ||
| Q1 25 | 29.8% | -48.3% | ||
| Q4 24 | 31.7% | -38.9% | ||
| Q3 24 | 29.7% | -49.5% | ||
| Q2 24 | 27.0% | -40.7% | ||
| Q1 24 | 29.7% | -46.4% |
| Q4 25 | 16.5% | -29.5% | ||
| Q3 25 | 15.4% | -11.8% | ||
| Q2 25 | 19.0% | -46.0% | ||
| Q1 25 | 16.9% | -49.5% | ||
| Q4 24 | 21.0% | -39.5% | ||
| Q3 24 | 19.2% | -49.6% | ||
| Q2 24 | 18.4% | -39.2% | ||
| Q1 24 | 17.9% | -47.7% |
| Q4 25 | $0.97 | $-0.09 | ||
| Q3 25 | $0.86 | $-0.03 | ||
| Q2 25 | $0.95 | $-0.13 | ||
| Q1 25 | $1.00 | $-0.12 | ||
| Q4 24 | $1.22 | $-0.11 | ||
| Q3 24 | $1.09 | $-0.10 | ||
| Q2 24 | $0.98 | $-0.08 | ||
| Q1 24 | $0.98 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $1.0B |
| 总债务越低越好 | $1.0B | $152.4M |
| 股东权益账面价值 | $1.8B | $1.7B |
| 总资产 | $3.5B | $2.3B |
| 负债/权益比越低杠杆越低 | 0.56× | 0.09× |
8季度趋势，按日历期对齐
| Q4 25 | $62.4M | $1.0B | ||
| Q3 25 | $119.1M | $976.7M | ||
| Q2 25 | $139.5M | $688.1M | ||
| Q1 25 | $97.9M | $428.4M | ||
| Q4 24 | $50.9M | $419.0M | ||
| Q3 24 | $51.5M | $442.4M | ||
| Q2 24 | $34.3M | $496.8M | ||
| Q1 24 | $46.5M | $492.5M |
| Q4 25 | $1.0B | $152.4M | ||
| Q3 25 | $993.1M | $347.0M | ||
| Q2 25 | $992.7M | $346.5M | ||
| Q1 25 | $992.4M | $345.9M | ||
| Q4 24 | $992.0M | $345.4M | ||
| Q3 24 | $1.1B | $61.2M | ||
| Q2 24 | $1.1B | $64.2M | ||
| Q1 24 | $1.1B | $66.8M |
| Q4 25 | $1.8B | $1.7B | ||
| Q3 25 | $1.8B | $1.3B | ||
| Q2 25 | $1.9B | $688.5M | ||
| Q1 25 | $1.8B | $431.3M | ||
| Q4 24 | $1.8B | $382.5M | ||
| Q3 24 | $1.7B | $419.8M | ||
| Q2 24 | $1.7B | $455.2M | ||
| Q1 24 | $1.7B | $478.9M |
| Q4 25 | $3.5B | $2.3B | ||
| Q3 25 | $3.4B | $2.2B | ||
| Q2 25 | $3.4B | $1.6B | ||
| Q1 25 | $3.4B | $1.3B | ||
| Q4 24 | $3.3B | $1.2B | ||
| Q3 24 | $3.3B | $1.2B | ||
| Q2 24 | $3.3B | $1.2B | ||
| Q1 24 | $3.3B | $1.2B |
| Q4 25 | 0.56× | 0.09× | ||
| Q3 25 | 0.54× | 0.27× | ||
| Q2 25 | 0.54× | 0.50× | ||
| Q1 25 | 0.54× | 0.80× | ||
| Q4 24 | 0.55× | 0.90× | ||
| Q3 24 | 0.61× | 0.15× | ||
| Q2 24 | 0.65× | 0.14× | ||
| Q1 24 | 0.68× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $-114.2M |
| 自由现金流率自由现金流/营收 | 26.6% | -63.6% |
| 资本支出强度资本支出/营收 | 1.1% | 27.6% |
| 现金转化率经营现金流/净利润 | 1.68× | — |
| 过去12个月自由现金流最近4个季度 | $267.2M | $-321.8M |
8季度趋势，按日历期对齐
| Q4 25 | $78.3M | $-64.5M | ||
| Q3 25 | $57.5M | $-23.5M | ||
| Q2 25 | $79.0M | $-23.2M | ||
| Q1 25 | $61.8M | $-54.2M | ||
| Q4 24 | $65.1M | $-2.4M | ||
| Q3 24 | $69.8M | $-30.9M | ||
| Q2 24 | $54.8M | $-13.0M | ||
| Q1 24 | $66.9M | $-2.6M |
| Q4 25 | $75.3M | $-114.2M | ||
| Q3 25 | $55.4M | $-69.4M | ||
| Q2 25 | $78.2M | $-55.3M | ||
| Q1 25 | $58.4M | $-82.9M | ||
| Q4 24 | $63.5M | $-23.9M | ||
| Q3 24 | $67.8M | $-41.9M | ||
| Q2 24 | $53.6M | $-28.3M | ||
| Q1 24 | $63.8M | $-21.8M |
| Q4 25 | 26.6% | -63.6% | ||
| Q3 25 | 20.2% | -44.8% | ||
| Q2 25 | 31.3% | -38.3% | ||
| Q1 25 | 19.7% | -67.6% | ||
| Q4 24 | 21.9% | -18.1% | ||
| Q3 24 | 23.9% | -40.0% | ||
| Q2 24 | 20.1% | -26.7% | ||
| Q1 24 | 23.0% | -23.5% |
| Q4 25 | 1.1% | 27.6% | ||
| Q3 25 | 0.8% | 29.6% | ||
| Q2 25 | 0.3% | 22.2% | ||
| Q1 25 | 1.2% | 23.4% | ||
| Q4 24 | 0.5% | 16.3% | ||
| Q3 24 | 0.7% | 10.5% | ||
| Q2 24 | 0.4% | 14.4% | ||
| Q1 24 | 1.1% | 20.7% |
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
